Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up
Objectives. To investigate the efficacy of infliximab in the treatment of severe calcium pyrophosphate deposition diseases (CPPD). Methods. Two patients with severe CPPD and diffuse idiopathic skeletal hyperostosis- (DISH-) like phenotype are described. Both patients were resistant to therapy with n...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Case Reports in Rheumatology |
| Online Access: | http://dx.doi.org/10.1155/2014/536856 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558057208414208 |
|---|---|
| author | Jácome Bruges-Armas Bruno F. Bettencourt Ana R. Couto Manuela Lima Ana M. Rodrigues Nathan Vastesaeger Matthew A. Brown |
| author_facet | Jácome Bruges-Armas Bruno F. Bettencourt Ana R. Couto Manuela Lima Ana M. Rodrigues Nathan Vastesaeger Matthew A. Brown |
| author_sort | Jácome Bruges-Armas |
| collection | DOAJ |
| description | Objectives. To investigate the efficacy of infliximab in the treatment of severe calcium pyrophosphate deposition diseases (CPPD). Methods. Two patients with severe CPPD and diffuse idiopathic skeletal hyperostosis- (DISH-) like phenotype are described. Both patients were resistant to therapy with nonsteroidal anti-inflammatory drugs (NSAIDs). Both patients were treated with infliximab, a TNF-α receptor antagonist, for nine years.
Results. Treatment with infliximab resulted in major clinical and laboratory improvements without relevant side effects.
Conclusions. These results suggest that infliximab may be an effective treatment of severe CPDD. |
| format | Article |
| id | doaj-art-ace663279c704685b3c86f9b39f2a8aa |
| institution | Kabale University |
| issn | 2090-6889 2090-6897 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Rheumatology |
| spelling | doaj-art-ace663279c704685b3c86f9b39f2a8aa2025-02-03T01:33:28ZengWileyCase Reports in Rheumatology2090-68892090-68972014-01-01201410.1155/2014/536856536856Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-UpJácome Bruges-Armas0Bruno F. Bettencourt1Ana R. Couto2Manuela Lima3Ana M. Rodrigues4Nathan Vastesaeger5Matthew A. Brown6SEEBMO, Hospital de Santo Espírito da Ilha Terceira, 9700 Angra do Heroísmo, PortugalSEEBMO, Hospital de Santo Espírito da Ilha Terceira, 9700 Angra do Heroísmo, PortugalSEEBMO, Hospital de Santo Espírito da Ilha Terceira, 9700 Angra do Heroísmo, PortugalGenetics & Arthritis Research Group (GARG), Institute for Molecular and Cell Biology (IBMC), 4150 Oporto, PortugalRheumatology Research Unit, Molecular Medicine Institute, Lisbon, PortugalMerck Sharp & Dohme, 1135 Brussels, BelgiumUniversity of Queensland, Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Brisbane, QLD 4192, AustraliaObjectives. To investigate the efficacy of infliximab in the treatment of severe calcium pyrophosphate deposition diseases (CPPD). Methods. Two patients with severe CPPD and diffuse idiopathic skeletal hyperostosis- (DISH-) like phenotype are described. Both patients were resistant to therapy with nonsteroidal anti-inflammatory drugs (NSAIDs). Both patients were treated with infliximab, a TNF-α receptor antagonist, for nine years. Results. Treatment with infliximab resulted in major clinical and laboratory improvements without relevant side effects. Conclusions. These results suggest that infliximab may be an effective treatment of severe CPDD.http://dx.doi.org/10.1155/2014/536856 |
| spellingShingle | Jácome Bruges-Armas Bruno F. Bettencourt Ana R. Couto Manuela Lima Ana M. Rodrigues Nathan Vastesaeger Matthew A. Brown Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up Case Reports in Rheumatology |
| title | Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up |
| title_full | Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up |
| title_fullStr | Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up |
| title_full_unstemmed | Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up |
| title_short | Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up |
| title_sort | effectiveness and safety of infliximab in two cases of severe chondrocalcinosis nine years of follow up |
| url | http://dx.doi.org/10.1155/2014/536856 |
| work_keys_str_mv | AT jacomebrugesarmas effectivenessandsafetyofinfliximabintwocasesofseverechondrocalcinosisnineyearsoffollowup AT brunofbettencourt effectivenessandsafetyofinfliximabintwocasesofseverechondrocalcinosisnineyearsoffollowup AT anarcouto effectivenessandsafetyofinfliximabintwocasesofseverechondrocalcinosisnineyearsoffollowup AT manuelalima effectivenessandsafetyofinfliximabintwocasesofseverechondrocalcinosisnineyearsoffollowup AT anamrodrigues effectivenessandsafetyofinfliximabintwocasesofseverechondrocalcinosisnineyearsoffollowup AT nathanvastesaeger effectivenessandsafetyofinfliximabintwocasesofseverechondrocalcinosisnineyearsoffollowup AT matthewabrown effectivenessandsafetyofinfliximabintwocasesofseverechondrocalcinosisnineyearsoffollowup |